Predicting responses to chemotherapy in breast cancer: from bench to bedside.
Recent progress in biotechnology, notably microarray analyses, makes it possible to examine the genome-based characteristics of tumors with different prognoses and predict responses to chemotherapy. Furthermore, pharmacogenomic techniques are expected to predict the optimal regimen for individual patients that will provide high benefits with reduced toxicity. Some predictive or prognostic tests for breast cancer are now moving from bench to bedside.
Division of Breast Surgery, National Cancer Center Hospital, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan. sakashi@ncc.go.jp
Sadako
S
Akashi-Tanaka
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor